Defining Cancer Drug Development Part II: A Discussion with FDA's Pazdur
FDA’s top oncology drug regulator says experience and history matter when making review decisions on supplemental indications for therapies already on the market.
FDA’s top oncology drug regulator says experience and history matter when making review decisions on supplemental indications for therapies already on the market.